semaglutide trial adolescents obesity 2022 50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj Full article: Semaglutide 2.4 mg

Food and Drug Administration by no later than the second quarter of this year, and investors will closely watch how that competition plays out

Data resource profile: the danish national prescription registry

Non-injectable GHK-Cu is permitted for 503A compounding by state-licensed pharmacies under the May 14, 2026 FDA reference document

GSH levels have been shown to decrease with ageing and in several age-related degenerative diseases and AD in particular (Harris et al., Whilst extracellular A plaques, NFT, inflammation in the form or reactive astrocytes and microglia, and neuronal loss are all consistent pathological features of AD, a mechanistic link between these factors is yet to be clarified

And what impact could they have on the global battle against obesity and beyond, in places you might not have thought about yet